You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

ELLENCE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ellence, and when can generic versions of Ellence launch?

Ellence is a drug marketed by Pfizer Inc and is included in one NDA.

The generic ingredient in ELLENCE is epirubicin hydrochloride. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the epirubicin hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ellence

A generic version of ELLENCE was approved as epirubicin hydrochloride by HIKMA on June 27th, 2007.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ELLENCE?
  • What are the global sales for ELLENCE?
  • What is Average Wholesale Price for ELLENCE?
Summary for ELLENCE
Drug patent expirations by year for ELLENCE
Drug Prices for ELLENCE

See drug prices for ELLENCE

Recent Clinical Trials for ELLENCE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Oregon Health and Science UniversityPhase 2
National Cancer Institute (NCI)Phase 2
OHSU Knight Cancer InstitutePhase 2

See all ELLENCE clinical trials

Pharmacology for ELLENCE

US Patents and Regulatory Information for ELLENCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc ELLENCE epirubicin hydrochloride INJECTABLE;INJECTION 050778-001 Sep 15, 1999 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer Inc ELLENCE epirubicin hydrochloride INJECTABLE;INJECTION 050778-002 Sep 15, 1999 AP RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.